Showing results (341-350 of 379) with videos related to
Sort By:
Pageof 38
Nature Biotechnology|August 19, 2021
Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in childrenJ Loske, J Röhmel, S Lukassen, et al.Ebiomedicine|July 11, 2025
Genotype and transcript processing of the tumour necrosis factor receptor TNFRSF1A in epithelial cells: implications for survival in cystic fibrosisAlexander Uden, Inga Dunsche, Sabina Janciauskiene, et al.Journal of Visualized Experiments : Jove|January 6, 2025
Operating and Biocontainment Procedures of a Facility for Laboratory Mice with a Natural Microbiome: Immunophenotyping ProcedureNatascha Drude, Kai Diederich, Claudia U Duerr, et al.The New England Journal of Medicine|November 8, 2019
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del AllelePeter G Middleton, Marcus A Mall, Pavel Dřevínek, et al.American Journal of Respiratory and Critical Care Medicine|May 10, 2022
Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del AllelesSimon Y Graeber, Diane M Renz, Mirjam Stahl, et al.ERJ Open Research|December 2, 2020
Multicentre feasibility of multiple-breath washout in preschool children with cystic fibrosis and other lung diseasesMirjam Stahl, Cornelia Joachim, Ines Kirsch, et al.Lancet (London, England)|November 5, 2019
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialHarry G M Heijerman, Edward F McKone, Damian G Downey, et al.American Journal of Respiratory and Critical Care Medicine|April 10, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Extension StudyCori L Daines, Deepika Polineni, Elizabeth Tullis, et al.The New England Journal of Medicine|October 19, 2018
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del AllelesJane C Davies, Samuel M Moskowitz, Cynthia Brown, et al.The European Respiratory Journal|June 20, 2024
Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del allelesMirjam Stahl, Martha Dohna, Simon Y Graeber, et al.Pageof 38